Evidence map›Paper›PMID 41294146›Full record

ArticleJournal of the American Heart Association2026

C-C Chemokine Receptor 4 Deficiency Protects Against Abdominal Aortic Aneurysm Formation.

Aga Krisnanda, Naoto Sasaki, Toru Tanaka, Ken Ito, Takuo Emoto, Takeshi Yoshida, Hilman Zulkifli Amin, Sayo Horibe, Gusty Rizky Teguh Ryanto, Noriaki Emoto and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Unmasking the Hidden Burden: Inflammation and Cardiovascular DiseaseJournal of the American Heart Association · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aga KrisnandaLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0009-0005-6417-2738
Naoto SasakiLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0002-7760-6129
Toru TanakaLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0002-1054-9211
Ken ItoLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.
Takuo EmotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0001-7425-4087
Takeshi YoshidaDivision of Advanced Medical Science Kobe University Graduate School of Science, Technology and Innovation Kobe Japan.
Hilman Zulkifli AminLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0003-0659-9678
Sayo HoribeLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0002-4111-2426
Gusty Rizky Teguh RyantoLaboratory of Clinical Pharmaceutical Science Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0003-0176-219X
Noriaki EmotoDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0001-6673-2616
Tomoya YamashitaDivision of Advanced Medical Science Kobe University Graduate School of Science, Technology and Innovation Kobe Japan.ORCID 0000-0003-0267-3842
Ken-Ichi HirataDivision of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine Kobe Japan.
Kazuhiko MatsuoDivision of Chemotherapy, Faculty of Pharmacy Kindai University Higashi-osaka Osaka Japan.ORCID 0000-0001-5782-5300
Takashi NakayamaDivision of Chemotherapy, Faculty of Pharmacy Kindai University Higashi-osaka Osaka Japan.ORCID 0000-0002-8493-899X
Yoshiyuki RikitakeLaboratory of Medical Pharmaceutics Kobe Pharmaceutical University Kobe Japan.ORCID 0000-0001-7207-4656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe dysregulated immune system, which drives chronic vascular inflammation and remodeling, plays a critical role in the pathogenesis of abdominal aortic aneurysm (AAA). CCR4 (C-C chemokine receptor 4), which is predominantly expressed on T cells and mediates their responses, has been shown to protect against inflammatory diseases including atherosclerosis. However, its role in AAA remains unknown.

methodsBy analyzing hypercholesterolemic CCR4-deficient (

resultsGenetic deletion of CCR4 on an

conclusionsCCR4 may serve as a potential therapeutic target for AAA.

Indexed as

Aorta, AbdominalAortic Aneurysm, AbdominalReceptors, CCR4Angiotensin IIAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLMice, KnockoutMice, Knockout, ApoEAngiotensin IICcr4 protein, mouseReceptors, CCR4abdominal aortic aneurysmchemokine receptorimmunologyinflammationT cells

Identifiers

PMID41294146
PMCPMC13055660

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.